FINNENCE ▪ THE WIRE FILE
THE WIRE · № 73537
News■ Unclear/unknown
VVVV IPO News - Cavity treatment provider vVardis files for an estimated $200 million US IPO
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-09 18:12 UTC
LAST UPDATE2026-10-09 18:12 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A $200M IPO filing for a cavity-treatment provider adds to healthcare issuance but the text gives no pricing or valuation detail.
Dental-care provider files for US IPO
CATALYST TO WATCH
Pricing range and roadshow demand
MAIN RISK
IPO postponed or priced below range
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Dental Firm vVardis Files for US IPO Showing Narrowing Loss2026-10-09 17:41 UTC
Dental Firm vVardis Files for US IPO Showing Narrowing Loss2026-10-09 17:41 UTC
←CORRELATIONshares Healthcare
TRex rakes in $117M IPO, while Retension reveals $45M listing2026-10-09 08:29 UTC
TRex rakes in $117M IPO, while Retension reveals $45M listing2026-10-09 08:29 UTC
←CORRELATIONshares Healthcare
City Therapeutics is seeking up to $185 million in a U.S. IPO for its gene-silencing drugs2026-10-09 12:34 UTC
City Therapeutics is seeking up to $185 million in a U.S. IPO for its gene-silencing drugs2026-10-09 12:34 UTC
←CORRELATIONshares Healthcare
City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut2026-10-09 14:15 UTC
City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut2026-10-09 14:15 UTC
←CORRELATIONshares Healthcare
LUX Infusion Expands Access to Hemophilia Care with Qfitlia (fitusiran)2026-10-09 14:37 UTC
LUX Infusion Expands Access to Hemophilia Care with Qfitlia (fitusiran)2026-10-09 14:37 UTC
←CORRELATIONshares Healthcare
Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger2026-10-09 15:05 UTC
Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger2026-10-09 15:05 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.